- Opinion
- [Reporter’s Eye] How was working from home for a year?
- by Kim, Jin-Gu Mar 31, 2021 06:09am
- A year has passed since the COVID-19 has bled into people’s daily lives. The pharmaceutical industry also has faced big changes and working from home was one the biggest changes. Although it was forcefully introduced, the work from home system, unlike the beginning of the outbreak, became a norm&8212;the office staffs have been working
- Opinion
- [Editor’s View] One year after the pandemic
- by Chon, Seung-Hyun Mar 25, 2021 05:58am
- A year has passed since COVID-19 hit the world. About this time last year, when the World Health Organization (WHO) declared a global pandemic of COVID-19, the KOSPI index dropped to the 1400 line. But suddenly, the KOSPI index recovered to 3000. On March 19 of last year, the KRX healthcare index, composed of major pharmaceutical and bio
- Opinion
- [Reporter’s Eye] For unbiased KPBMA ethics committee
- by Mar 19, 2021 06:28am
- Industry-representing associations are often perplexed among various opinions of businesses of all sizes. Unlike small and medium-sized companies urging the regulation to be versatile for the survival of many companies, large corporations focus more on industry support and advancement. Often, the companies express contrasting opinions on a s
- Opinion
- [Reporter's View] BINEX & NDMA Phobia
- by Lee, Jeong-Hwan Mar 12, 2021 06:21am
- It was said that it should never be done and it was malicious because it was deliberate. This is a concern from the National Assembly, the government, and the pharmaceutical industry looking at the situation of BINEX, which violated the pharmaceutical affairs law due to suspicion of manufacturing method and dosage manipulation, which is also
- Opinion
- [Reporter’s Eye] Needs transparency in Cancer Committee
- by Eo, Yun-Ho Mar 8, 2021 06:20am
- The cases of healthcare reimbursement expansion on novel drug in South Korea has plummeted last year. The drug use has diversified but the actual use volume has not been increased. A survey on pharmaceutical reimbursement status found the increase in reimbursement expansion for each item in 2020 compared to 2019 has plunged by 70 percen
- Opinion
- [Reporter’s Eye] Be aware of fake news trampling the hope
- by An, Kyung-Jin Mar 5, 2021 06:26am
- Recently, the South Korean media industry is intensely disputing over a bill imposing punitive damages. Democratic Party Lawmaker Noh Woong-rae issued a legislative notice on a bill to include general media and portal websites as subjects for the punitive damages, which awards compensation valuing maximum of triple the damages to a prevailin
- Opinion
- [Reporter’s View] KDCA’s dilemma on using AZ vaccine
- by Kim, Jin-Gu Feb 17, 2021 05:39am
- The last call is to be made by the hand of Korea Disease Control and Prevention Agency (KDCA). On Feb. 10, South Korea’s Ministry of Food and Drug Safety (MFDS) finalized the authorization on AstraZeneca’s COVID-19 vaccine. The ministry included a warning for inoculating an age group over 65 that ‘the vaccination should be carefully consi
- Opinion
- [Reporter’s View] The transparency in COVID-19 drug review
- by Lee, Tak-Sun Feb 1, 2021 06:16am
- The public is keeping a close eye on the South Korean Ministry of Food and Drug Safety (MFDS) approving the COVID-19 vaccine and treatment. Especially because the pharmaceuticals and their efficacy have been controversial overseas, the public’s interest is heightened on the result of the health authority’s evaluation. To guarantee an
- Opinion
- [Editor’s View] The key to Xofluza pricing negotiation
- by Nho, Byung Chul Jan 26, 2021 06:00am
- A novel breakthrough influenza treatment Xofluza (baloxavir) by Roche is in a deadlock. Due to COVID-19 pandemic and conditional non-reimbursement status, the flu drug is struggling with the sales dip and marketing. Even before the launch, the drug was expected to easily take over Tamiflu’s market with significantly improved administration
- Opinion
- [Reporter's View] Yuhan's Open Innovation Success Model
- by Kim, Jin-Gu Jan 20, 2021 06:02am
- Until only five years ago, Yuhan was the No. 1 pharmaceutical company in Korea, but it was criticized for being a company that sells foreign drugs and only acts as a wholesaler. The company had very few pipelines. However, since President Lee Jung-hee took office in 2015, Yuhan's new drug pipeline has increased to 29 as of the end of last
